106 results
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
9 May 24
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
4:10pm
Trial Data at Macula Society 2024:
◦In February 2024, we announced positive preliminary efficacy and safety data from the ongoing LUNA Phase 2 trial
8-K
EX-99.1
du47s0uuppjgf
18 Mar 24
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
4:08pm
8-K
exgvs
8 Feb 24
Regulation FD Disclosure
8:45am
8-K
EX-99.1
zvthi
8 Feb 24
Regulation FD Disclosure
8:45am
8-K/A
eqen i1opn0ai0738c
4 Dec 23
Departure of Directors or Certain Officers
4:09pm
8-K
EX-99.1
dtc3gjmxdn
9 Nov 23
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
4:07pm
8-K
6spbis12 1zf5ou9o8h
6 Nov 23
Departure of Directors or Certain Officers
4:10pm
8-K
EX-99.1
xswvdz w9to
10 Aug 23
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
4:09pm
424B5
gozydb
11 May 23
Prospectus supplement for primary offering
4:43pm
8-K
EX-99.1
cwmc j24vh5sry1fcc
11 May 23
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
4:10pm